Patient Derived Cancer Model (PDCM) Finder

项目概要-患者衍生癌症模型（PDCM） 癌症研究中显著增长的一个领域是低传代人类癌细胞的多样性和体积 细胞系、三维类器官培养物和称为患者来源的肿瘤异种移植物（PDX）。 癌症模型（PDCM）。因此，该项目将汇总、协调和整合各种PDCM数据， 通过包含新模型扩展我们以前的资源PDX，使这些FAIR（Findable， 兼容性、互操作性、可重用性）和云可访问性，例如在NCI Research 共享资源PCDM SDK将解决在许多存储库中搜索模型、不兼容 标准使得模型的分析和重复使用变得困难，分子数据集注释不足 阻止基于云的分析的信息，以及在提供FAIR时需要更多社区意识- 合规数据，以最大限度地发挥其工作的影响。为了应对这些挑战，PDCM有三项任务：1） 通过增强我们当前的资源来提供PDCM，使癌症研究人员能够查找和访问模型 2）聚合和集成PDCM数据集，以确保NCI癌症的互操作性和可重用性 研究共享，以及3）在项目的所有阶段进行有针对性的社区外展，以确定 优先考虑需求，指导开发并促进PDCM可持续发展资源。预期 结果是，用户将能够根据社区定义查找、分组和定位所有类型的PDCM模型 属性（例如诊断、致癌突变）;探索和下载分子数据摘要和药物 来自PDCM门户的响应数据;在云上聚合和分析协调的PDCM分子数据集 基于分析平台。这将通过允许医生和研究人员找到PDCM来加速癌症研究 最适合他们的患者和/或研究问题的数据，并探索新的治疗途径， 患者

Project Summary - Patient Derived Cancer Model (PDCM) Finder An area of significant growth in cancer research is the diversity and volume of low passage human cancer cell lines, three-dimensional organoid cultures and patient-derived tumor xenografts (PDX) known as Patient Derived Cancer Models (PDCM). This project will therefore aggregate, harmonize and integrate diverse PDCM data, extending our previous resource PDX Finder by inclusion of novel models, making these FAIR (Findable, Accessible, Interoperable, Reusable) compliant and cloud accessible, for example in the NCI Research Commons. PCDM Finder will address challenges with searching over many repositories for models, incompatible standards that make analysis and reuse of models difficult, molecular datasets annotated with insufficient information that prevent cloud-based analyses and the need for more community awareness in providing FAIR- compliant data to maximize the impact of their work. To address these challenges, PDCM Finder has 3 tasks: 1) Enable cancer researchers to Find and Access models by enhancing our current resource to deliver the PDCM Finder, 2) Aggregate and Integrate PDCM datasets to ensure Interoperability and Reusability for the NCI Cancer Research Commons, and 3) Perform targeted community outreach during all stages of the project to determine and prioritize requirements, guide development and promote the PDCM Finder resource. The expected outcomes are users will be able to find, group and locate PDCM models of all types based on community defined attributes (e.g. diagnosis, oncogenic mutation); explore and download molecular data summaries and drug response data from the PDCM portal; aggregate and analyze harmonized PDCM molecular datasets on cloud based analysis platforms. This will accelerate cancer research by allowing doctors and researchers to find PDCM data that best matches their patients and/or research questions and explore new therapeutic avenues for patients.